Similar in some ways to chronic myelogenous leukemia, juvenile myelomonocytic leukemia (JMML) is rare a type of leukemia in which bone marrow production becomes very disregulated. The bone marrow produces immature myelocytes and monocytes, types of infection-fighting white blood cells, which crowd out healthy cells.
JMML generally causes a more severe disruption in blood counts early in the disease than CML and it is not as responsive to treatment.
Patients with juvenile myelomonocytic leukemia are treated at Dana-Farber/Boston Children's Cancer and Blood Disorders Center through the Leukemia Program. Continue reading to learn more about JMML or visit the Leukemia Program homepage to learn about our expertise and treatment options for this condition.
Children usually don’t have any symptoms in the early stages of JMML. When they do occur, a child may experience them over a period of months or even years.
The most common symptoms of CML include:
JMML is often diagnosed during a routine blood test conducted for other reasons. Other diagnostic tests include:
After all tests are completed, doctors will be able to outline the best treatment options.
Treatment options for JMML may include (alone or in combination):
Through ongoing education, care and support, we are preparing cancer survivors for the road ahead. Learn about our extensive services for survivors of pediatric cancer.